Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Top-line results from the randomized, double-blind confirmatory Phase III study (ERADICATE Hp2 study) with TALICIA® are expected before year’s end The ERADICATE Hp2 study enrolled 455 patients with...
-
Key Highlights: Top-line results from confirmatory Phase III study with TALICIA® for H. pylori infection on track to be announced in the fourth quarter of 2018 Positive top-line results from Phase...
-
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 24, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty...
-
Once granted, the new formulation patent is expected to be valid until at least 2033RHB-106 is an encapsulated bowel preparation with worldwide rights licensed to Salix Pharmaceuticals RedHill and...
-
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty...
-
Once granted, the new patent, which covers both RHB-104 and RHB-204, is expected to be valid until at least 2029 RedHill recently announced positive top-line results from the randomized, double-blind,...
-
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 09, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty...
-
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
-
Primary endpoint successfully achieved - superior remission rate at week 26 in patients treated with RHB-104 (p= 0.013) Key secondary endpoints also met, demonstrating consistent benefit to Crohn’s...
-
Mytesi® is an FDA-approved anti-diarrheal prescription drug indicated for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on anti-retroviral therapy (ART)Mytesi® is the...